Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-small Cell Lung Cancer

Immutep Limited announced it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with the standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line NSCLC.